Living Cell Technologies Limited
Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up … Read more
Living Cell Technologies Limited (LVCLF) - Total Assets
Latest total assets as of June 2025: $2.40 Million USD
Based on the latest financial reports, Living Cell Technologies Limited (LVCLF) holds total assets worth $2.40 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Living Cell Technologies Limited - Total Assets Trend (2004–2025)
This chart illustrates how Living Cell Technologies Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Living Cell Technologies Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Living Cell Technologies Limited's total assets of $2.40 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $3.79K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Living Cell Technologies Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Living Cell Technologies Limited's current assets represent 100.0% of total assets in 2025, an increase from 48.2% in 2004.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 37.1% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2004.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Living Cell Technologies Limited Competitors by Total Assets
Key competitors of Living Cell Technologies Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Living Cell Technologies Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Living Cell Technologies Limited generates 0.04x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Living Cell Technologies Limited is currently not profitable relative to its asset base.
Living Cell Technologies Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.13 | 17.89 | 9.88 |
| Quick Ratio | 14.13 | 17.89 | 9.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.23 Million | $ 3.01 Million | $ 2.76 Million |
Living Cell Technologies Limited - Advanced Valuation Insights
This section examines the relationship between Living Cell Technologies Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.40 |
| Latest Market Cap to Assets Ratio | 1.78 |
| Asset Growth Rate (YoY) | -24.9% |
| Total Assets | $2.40 Million |
| Market Capitalization | $4.27 Million USD |
Valuation Analysis
Above Book Valuation: The market values Living Cell Technologies Limited's assets above their book value (1.78 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Living Cell Technologies Limited's assets decreased by 24.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Living Cell Technologies Limited (2004–2025)
The table below shows the annual total assets of Living Cell Technologies Limited from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $2.40 Million | -24.87% |
| 2024-06-30 | $3.19 Million | -24.20% |
| 2023-06-30 | $4.21 Million | -1.45% |
| 2022-06-30 | $4.27 Million | +160.27% |
| 2021-06-30 | $1.64 Million | -51.57% |
| 2020-06-30 | $3.39 Million | -41.12% |
| 2019-06-30 | $5.76 Million | -24.30% |
| 2018-06-30 | $7.61 Million | -12.49% |
| 2017-06-30 | $8.69 Million | +37.73% |
| 2016-06-30 | $6.31 Million | +15.52% |
| 2015-06-30 | $5.46 Million | -43.46% |
| 2014-06-30 | $9.66 Million | -32.03% |
| 2013-06-30 | $14.22 Million | -8.41% |
| 2012-06-30 | $15.52 Million | +107.76% |
| 2011-06-30 | $7.47 Million | +7.61% |
| 2010-06-30 | $6.94 Million | +6.82% |
| 2009-06-30 | $6.50 Million | -46.90% |
| 2008-06-30 | $12.24 Million | +220.67% |
| 2007-06-30 | $3.82 Million | -10.35% |
| 2006-06-30 | $4.26 Million | +7.95% |
| 2005-06-30 | $3.94 Million | +201.25% |
| 2004-06-30 | $1.31 Million | -- |